drugset

drugset / Trial / NCT03246451

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

NCT03246451 ↗

Completed 15 enrolled University Hospital, Gentofte, Copenhagen University of Copenhagen · collab

RandomizedCrossoverTriple-blindBasic science

Summary

Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.

Timeline

Start: 2017-07-01
Primary completion: 2017-12-10
Completion: 2017-12-10

Publications

Hansen LS, Gasbjerg LS, Bronden A, Dalsgaard NB, Bahne E, Stensen S, Hellmann PH, Rehfeld JF, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsboll T, Knop FK. The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial. Eur J Endocrinol. 2024 Aug 5;191(2):192-203. doi: 10.1093/ejendo/lvae095.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avexitide	Peptide	—	Intravenous
Subject	Metformin	Small molecule	2000 mg	Oral

Indications